Process areas for improvement ID'd in early prostate cancer

August 22, 2012
Process areas for improvement ID'd in early prostate cancer
For men with early prostate cancer undergoing expectant management, compliance with RAND structural indicators is high, but there is considerable variability in compliance with process indicators, according to a study published in the September issue of The Journal of Urology.

(HealthDay) -- For men with early prostate cancer undergoing expectant management, compliance with RAND structural indicators is high, but there is considerable variability in compliance with process indicators, according to a study published in the September issue of The Journal of Urology.

Jamie Ritchey, M.P.H., from the American College of Surgeons in Chicago, and colleagues abstracted medical records data and measured compliance with the RAND-developed quality indicators (structure and process). Data were reviewed for 13,876 men with early-stage prostate cancer undergoing expectant management in 2000 to 2001.

The researchers found that there was high compliance with structural indicators (greater than 80 percent), while compliance with process indicators varied (19 to 87 percent). Differences in process indicators were seen for models based on hospital type and , but not for age, race, or .

"Using the RAND quality indicators, this study revealed several process areas for quality improvement among men with early-stage prostate cancer on expectant management in the United States," the authors write. "Efforts to improve the quality of early-stage care need to move beyond the paradigm of age, race, and insurance status."

One author disclosed financial ties to diagnostics manufacturers.

Explore further: Excess body weight associated with increased risk for prostate cancer recurrence

More information: Abstract
Full Text
Editorial (subscription or payment may be required)

Related Stories

Excess body weight associated with increased risk for prostate cancer recurrence

April 3, 2012
Researchers have found an association between excess body weight and an increased risk for cancer recurrence in men with clinically localized prostate cancer.

Relief of urinary symptoms is an underappreciated benefit of early stage prostate cancer treatment

May 20, 2012
Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.